RCS - Ondine Biomedical - Second Quebec Hospital Adopts Steriwave

Ondine BiomedicalAnnouncement

19/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250619:nRSS4833Na&default-theme=true

RNS Number : 4833N  Ondine Biomedical Inc.  19 June 2025

19 June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Second Quebec Hospital Adopts Steriwave

Hôtel-Dieu de Sherbrooke Becomes Second Hospital in Quebec to Adopt Ondine's
Steriwave(®) Photodisinfection as Standard of Care for Orthopedic Surgeries

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that Hôtel-Dieu de
Sherbrooke has adopted Steriwave(®) nasal photodisinfection as standard of
care for its orthopedic surgeries. This makes Hôtel-Dieu the second hospital
in Quebec to formally adopt this innovative infection prevention technology
into its routine surgical protocols. Steriwave is now in six of Canada's top
ten largest hospitals.

The Hôtel-Dieu implementation follows the successful deployment of Steriwave
at Hôpital Fleurimont (CIUSSS de l'Estrie - CHUS), the first in Quebec to use
Steriwave for high-risk neuro and spine surgery patients. Under the leadership
of Dr. Bernard LaRue and his clinical research team, Fleurimont reported a
78.8% reduction in surgical site infections (SSIs) among patients receiving
pre-operative Steriwave therapy. These compelling results, presented at the
25th Annual Scientific Conference of the Canadian Spine Society in February
2025, highlight Steriwave's efficacy, safety, and ease of integration into
preoperative workflows. In addition to those results in Quebec, Mid Yorkshire
Teaching NHS Trust in the UK reported a 71% reduction in joint surgery
infections following the adoption of Steriwave protocols.

With the adoption of Steriwave by Hôtel-Dieu, the Estrie region of Quebec
continues to demonstrate leadership in infection control. The hospital joins a
growing number of healthcare institutions in Canada and in other countries
implementing Steriwave as part of their strategies to reduce SSIs and enhance
patient outcomes. Steriwave's rapid, full-spectrum nasal decolonization
provides superior protection without contributing to antimicrobial resistance
or requiring patient compliance.

SSIs remain a major healthcare challenge. Approximately 69% of SSIs are caused
by pathogens that colonize the nasal passages,( 1-3  )highlighting the nose
as a critical reservoir for infection-causing microbes. This underscores the
importance of effective pre-surgical nasal decolonization strategies. At the
same time, there is increasing need for technologies that do not rely on
patient compliance-particularly given the variability of topical antibiotic
use and growing antimicrobial resistance.

Carolyn Cross, CEO of Ondine Biomedical, stated:

"We are proud to support Hôtel-Dieu de Sherbrooke as the second Quebec
hospital to adopt nasal photodisinfection as standard of care. In today's
healthcare environment, where antibiotic resistance is a mounting threat,
adopting innovative and proven infection prevention strategies is more
important than ever. We commend the hospital's leadership and dedication to
patient safety."

Steriwave is a painless non-antibiotic antimicrobial therapy that destroys
harmful pathogens in the nose without promoting resistance or relying on
patient compliance. The treatment involves applying a proprietary
photosensitive agent to each nostril followed by illumination with a specific
wavelength of red light. The process takes only minutes and destroys bacteria,
viruses, and fungi, including drug-resistant organisms, in the nasal cavity.

Steriwave is approved in Canada, Europe (CE mark), Australia, Mexico, and
several other countries for use in nasal decolonization. In the United States,
Steriwave has been granted Qualified Infectious Disease Product (QIDP)
designation and Fast Track status by the U.S. FDA and is currently undergoing
clinical trials to support regulatory approval.

 

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

 i  CDC. HAI Pathogens and Antimicrob Resist Report, 2018-2021. (link
(https://www.cdc.gov/nhsn/hai-report/index.html) )

 ii  Nature. 2012;486:207-214. (link
(https://www.nature.com/articles/nature11234) )

 iii  Biomedicines. 2022 Dec 26;11(1):54. (link
(https://www.mdpi.com/2227-9059/11/1/54/review_report) )

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADDGDLCXBDGUI